Welcome to our dedicated page for Theralase Technologies news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on Theralase Technologies stock.
Theralase Technologies Inc. (TLTFF) is a clinical stage pharmaceutical company whose news flow centers on the development of light, radiation, sound and drug-activated small molecule compounds for the destruction of cancers, bacteria and viruses. Company announcements frequently highlight progress in its oncology and antiviral programs, financing activities and collaborations with partners.
Investors following TLTFF news can expect regular updates on Theralase’s Phase II clinical study in Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in situ, where the company is clinically investigating light-activated Ruvidar. Releases have included interim clinical response data, enrollment status and timelines for data lock and regulatory submissions as described by the company.
News items also cover preclinical research, such as studies of radiation-activated Rutherrin in multiple cancer models and peer-reviewed data on Ruvidar as an antiviral candidate against Herpes Simplex Virus Type 1. These updates summarize scientific findings, mechanisms under investigation and potential implications for future development, as presented by Theralase and collaborating researchers.
From a capital markets perspective, Theralase’s news includes details of non-brokered private placements, warrant extensions and short-term loans, along with the intended use of proceeds for clinical studies, development work and working capital. The company also issues reminders and summaries for investor conference calls where management discusses financial statements and operational milestones.
This TLTFF news page aggregates these disclosures so readers can review company-stated clinical, scientific and financing developments in one place and monitor how Theralase describes the evolution of its small molecule programs over time.
Theralase Technologies has announced new patient enrollment for their Phase II clinical study on non-muscle invasive bladder cancer (NMIBC) at the McGill University Health Centre. To date, 12 patients have been treated, with 25% achieving complete response and 25% showing partial response. The company is advancing discussions to open five additional clinical sites in the U.S. and has resubmitted their Fast Track Approval application to the FDA after an initial denial. The study aims to enroll approximately 100 patients and evaluate efficacy, safety, and duration of treatment responses.
Theralase Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) has provided details for registered shareholders and proxyholders to vote at its virtual Annual General and Special Meeting on September 24, 2020, at 4:30 PM EDT. Only those on record as of August 21, 2020, are eligible to vote. Attendees must connect online and dial in to participate. Each shareholder has one vote per common share. Theralase focuses on developing light-activated Photo Dynamic Compounds for treating cancers and infections.
Theralase Technologies Inc. (TSXV:TLT, OTCQB:TLTFF) reported a 21% decline in total revenue for the first half of 2020, totaling $293,453 compared to $370,436 in 2019, mainly due to pandemic-related disruptions. Canadian revenue dropped by 23%, while US revenue plunged 49%. The company's net loss widened to $3,267,624, driven by 70% increase in R&D expenses linked to ongoing clinical studies. Despite challenges, Theralase has initiated four Canadian clinical sites for its Phase II study and is exploring additional US sites.
Theralase Technologies Inc. (TSXV:TLT, OTCQB:TLTFF) has announced amendments to its standard by-laws, aimed at aligning with the current provisions of the Canada Business Corporations Act and corporate governance standards. The changes, which include housekeeping amendments, will be subject to shareholder approval at the upcoming annual meeting on September 24, 2020. These adjustments reflect the company’s commitment to maintaining compliance and enhancing governance.
Theralase Technologies has released its Quarterly Newsletter, detailing updates on its Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study. The Company focuses on developing light-activated Photo Dynamic Compounds (PDC) for cancer treatment. This newsletter highlights the Company’s progress over the last quarter and can be accessed on their website. Theralase continues to pursue innovative solutions for safely and effectively treating various cancers, underscoring its commitment to research and development.